End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
108 TWD | +0.47% | -4.42% | -.--% |
Sales 2024 * | 18.33B 569M 775M | Sales 2025 * | 21.17B 657M 894M | Capitalization | 79.6B 2.47B 3.36B |
---|---|---|---|---|---|
Net income 2024 * | 4.39B 136M 185M | Net income 2025 * | 6.2B 193M 262M | EV / Sales 2024 * | 4.72 x |
Net Debt 2024 * | 6.89B 214M 291M | Net Debt 2025 * | 2.64B 82.1M 112M | EV / Sales 2025 * | 3.89 x |
P/E ratio 2024 * |
17.1
x | P/E ratio 2025 * |
12.7
x | Employees | - |
Yield 2024 * |
1.75% | Yield 2025 * |
2.61% | Free-Float | 48.47% |
Latest transcript on Lotus Pharmaceutical Co., Ltd.
1 day | +0.47% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 14-09-28 | |
I ling Tian
DFI | Director of Finance/CFO | - | 16-10-31 |
Ying Ming Yue
COO | Chief Operating Officer | - | 22-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CHM | Chairman | 54 | 15-04-22 |
Director/Board Member | 60 | 14-08-10 | |
Director/Board Member | 61 | 15-04-22 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.36% | 694B | |
+29.71% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.53% | 239B | |
-3.23% | 209B | |
+10.04% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- 1795 Stock
- 1795 Stock